325773-41-9Relevant academic research and scientific papers
SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS
-
, (2013/03/26)
The invention provides a compound having the structure (I), wherein A is a substituted or unsubstituted ring; Z is present or absent and when present is (II), wherein n is 0, 1, 2, 3, or 4; Y is -(CR11R12)-, -NH(CR11R12)- or -O(CR11R12)- wherein R11 and R12 are each hydrogen or combine to form a carbonyl; and wherein R1 to R10 are herein as described.
Synthesis and pharmacological evaluation of aminopyrimidine series of 5-HT1A partial agonists
Dounay, Amy B.,Barta, Nancy S.,Bikker, Jack A.,Borosky, Susan A.,Campbell, Brian M.,Crawford, Terry,Denny, Lynne,Evans, Lori M.,Gray, David L.,Lee, Pil,Lenoir, Edward A.,Xu, Wenjian
scheme or table, p. 1159 - 1163 (2009/08/07)
Aminopyrimidine 2 (4-(1-(2-(1H-indol-3-yl)ethyl)piperidin-3-yl)-N-cyclopropylpyrimidin-2-amine) emerged from a high throughput screen as a novel 5-HT1A agonist. This compound showed moderate potency for 5-HT1A in binding and functional assays, as well as moderate metabolic stability. Implementation of a strategy for improving metabolic stability by lowering the lipophilicity (c Log D) led to identification of methyl ether 31 (4-(1-(2-(1H-indol-3-yl)ethyl)piperidin-3-yl)-N-(2-methoxyethyl)pyrimidin-2-amine) as a substantially improved compound within the series.
3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists
Contour-Galcera, Marie-Odile,Sidhu, Alban,Plas, Pascale,Roubert, Pierre
, p. 3555 - 3559 (2007/10/03)
Novel 3-thio-1,2,4-triazoles have been obtained via a solution-phase parallel synthesis strategy, affording potent non-peptidic human somatostatin receptor subtypes 2 and 5 agonists.
